Renal function in tenofovir-exposed and tenofovir-unexposed patients receiving highly active antiretroviral therapy in the HIV outpatient study

Journal of the International Association of Physicians in AIDS Care

Volumn 6, Issue 3, 2007, Pages 178-187

  Young, Benjamin ^a   Buchacz, Kate ^b   Baker, Rose K ^c   Moorman, Anne C ^b   Wood, Kathy C ^c   Chmiel, Joan ^d   Brooks, John T ^b  

^a ROSE MEDICAL CENTER   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c CERNER CORPORATION   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

creatinine clearance; highly active antiretroviral therapy; renal disease; tenofovir; toxicity

Indexed keywords

ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CREATININE; PHOSPHONIC ACID DERIVATIVE; TENOFOVIR;

HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN; OUTPATIENT;

ADENINE; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CREATININE; HIV INFECTIONS; HUMANS; ORGANOPHOSPHONATES; OUTPATIENTS; TENOFOVIR;

EID: 48749104675     PISSN: 15451097     EISSN: 15570886     Source Type: Journal    
DOI: 10.1177/1545109707300676     Document Type: Article

References (25)

1. Gallant JE, Deresinski S. Tenofovir disoprox (Pubitemid 37267211)
2. Panel on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: http://AIDSinfo.nih.gov. Accessed March 17, 2006.
3. Kahn J., Lagakos S., Wulfsohn M., et al. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial. JAMA. 1999 ; 282: 2305-2312. (Pubitemid 30013061)
4. Ho ES, Lin DC, Mendel DB, Cihlar T. Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. J Am Soc Nephrol. 2000 ; 11: 383-393. (Pubitemid 30115068)
5. Van Rompay KK, Brignolo LL, Meyer DJ, et al. Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques. Antimicrob Agents Chemother. 2004 ; 48: 1469-1487. (Pubitemid 38544348)
6. Tarantal AF, Marthas ML, Shaw JP, Cundy K., Bischofberger N. Administration of 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) to gravid and infant rhesus macaques (Macaca mulatta): safety and efficacy studies. J Acquir Immune Defic Syndr Hum Retrovirol. 1999 ; 20: 323-333. (Pubitemid 29143025)
7. Schooley RT, Ruane P., Myers RA, et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS. 2002 ; 16: 1257-1263. (Pubitemid 34666660)
8. Squires K., Pozniak AL, Pierone G. Jr, et al. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial. Ann Intern Med. 2003 ; 139: 313-320.
9. Izzedine H., Hulot JS, Vittecoq D., et al. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients: data from a double-blind randomized active-controlled multicentre study. Nephrol Dial Transplant. 2005 ; 20: 743-746. (Pubitemid 40520651)
10. Gallant JE, Staszewski S., Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004 ; 292: 191-201. (Pubitemid 38917996)
11. Gallant JE, DeJesus E., Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006 ; 354: 251-260. (Pubitemid 43113030)
12. Peyriere H., Reynes J., Rouanet I., et al. Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr. 2004 ; 35: 269-273. (Pubitemid 38280652)
13. Izzedine H., Isnard-Bagnis C., Hulot JS, et al. Renal safety of tenofovir in HIV treatment-experienced patients. AIDS. 2004 ; 18: 1074-1076. (Pubitemid 38591202)
14. Zimmermann AE, Pizzoferrato T., Bedford J., et al. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis. 2006 ; 42: 283-290. (Pubitemid 43054205)
15. Antoniou T., Raboud J., Chirhin S., et al. Incidence of and risk factors for tenofovir-induced nephrotoxicity: a retrospective cohort study. HIV Med. 2005 ; 6: 284-290. (Pubitemid 41025294)
16. Gallant JE, Parish MA, Keruly JC, Moore RD Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis. 2005 ; 40: 1194-1198. (Pubitemid 40490248)
17. Winston A., Amin J., Mallon PW, et al. Minor changes in calculated creatinine clearance and anion-gap are associated with Tenofovir DF containing highly active antiretroviral therapy. HIV Med. 2006 ; 7: 105-111.
18. Gallant JE, Parish MA, Keruly JC, Moore RD Reply to Gupta. Clin Infect Dis. 2005 ; 41: 571-572.
19. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection: HIV Outpatient Study Investigators. N Engl J Med. 1998 ; 338: 853-860. (Pubitemid 28135961)
20. Cockcroft DW, Gault MH Prediction of creatinine clearance from serum creatinine. Nephron. 1976 ; 16: 31-41.
21. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002 ; 39: S1 - S266.
22. Division of AIDS table for grading the severity of adult and pediatric adverse events, December 2004. Available at: http://rcc.tech-res-intl.com/tox- tables.htm. Accessed March 17, 2006.
23. Jones R., Stebbing J., Nelson M., et al. renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control study. J Acquir Immune Defic Syndr. 2004 ; 37: 1489-1495. (Pubitemid 39602339)
24. Moreno S., Domingo P., Palacios R., et al. Renal safety of tenofovir disoproxil fumarate in HIV-1 treatment-experienced patients with adverse events related to prior NRTI use: data from a prospective, observational, multicenter study. J Acquir Immune Defic Syndr. 2006 ; 42: 385-387. (Pubitemid 44050022)
25. Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2005 ; 40: 1559-1585. (Pubitemid 40720806)